Akili, Inc.

Akili, Inc. (Nasdaq: DNAA) is a digital therapeutics company focused on software-based cognitive treatments, having completed its business combination with Social Capital Suvretta Holdings Corp. I — sponsored by Social Capital Suvretta LLC, a joint venture between Chamath Palihapitiya's Social Capital and Suvretta Capital Management — in August 2022. The SPAC priced its IPO in 2021 and targeted the healthcare technology and digital medicine sector. By the time of its April 2024 8-K filing, Akili had announced a definitive agreement to be acquired by Virtual Therapeutics, marking the conclusion of a strategic review process initiated after the company wound down its direct-to-consumer commercial operations. For full filing details, institutional data, and deal timelines on DNAA and hundreds of other SPAC transactions, sign up for complete access at SpacDesk.